The FDA has granted fast track designation to emiltatug ledadotin for advanced or metastatic breast cancer treatment, as ...

The top-line results of DESTINY Breast-04 are impressive - in patients with HER2-low metastatic breast cancer who received multiple lines of prior treatment, Enhertu (trastuzumab deruxtecan ...

The HER2-low and HER2-ultralow breast cancer subtype designations have led to a changed landscape in HER2-directed therapies, as well as a desire for more sensitive assays that may better quantify ...

HER2-negative breast cancers are HER2-low and potentially an additional 25% may be HER2-ultra-low. There are no targeted therapies specifically approved for patients with HER2-ultra-low expression ...

Mersana shares Phase 1 data on Emi-Le for TNBC and details FDA's Fast Track status for XMT-1660 in advanced HER2-low breast ...

Today we're going to tackle the HER2–ultra-low breast cancers. To join me in talking about that topic, I'm delighted to welcome Dr Francisco Esteva. Dr Esteva is a professor of medicine at the ...

REVEAL GENOMICS, S.L., a Barcelona-based biotechnology start-up seeking to revolutionize precision oncology through biomarker ...

CURE created a list of the top breast cancer stories of this year, including those focused on patient-reported outcomes and ...

This page includes links to articles highlighting the top breast cancer research published on Cancer Therapy Advisor in 2024.

The phase 3 DESTINY-Breast06 trial enrolled patients with HR+, HER2-low (immunohistochemistry (IHC) 1+ or IHC 2+/in situ hybridization negative) or HER2-ultra-low (IHC 0 with membrane staining ...